02307O-077630US 97-177-5

RECEIVED

SEP 2 4 2001

TECH CENTER 1600 2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

John Harada, et al.

Application No.: 09/516,052

Filed: March 1, 2000

For: LEAFY COTYLEDON1 GENES

AND THEIR USES

Examiner: C. Collins

Art Unit: 1638

RESPONSE TO RESTRICTION

REQUIREMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Office Action mailed August 16, 2001, applicants hereby elect with traverse the claims of Group II (claims 4-5, 23-24, 50-51 and 59-60) if claims 1, 21, 47 and 58 are included in Group II. If claims 1, 21, 47 and 58 are not included in Group II, Applicants elect with traverse Group I (claims 1-3, 9, 21-22, 28-29, 35-36, 39, 42-43, 46-49, 54-55, 58, 63 and 69).

REMARKS

1. Examination of claim 1-69 would not create an undue burden

Applicants respectfully submit that examination of claims 1-69 would not create an undue burden for the Examiner.

According to the MPEP, where claims can be examined together without undue burden, the Examiner must examine the claims on the merits even though they are directed to independent and distinct inventions. *See*, the MPEP at 803.01. In establishing that an "undue burden" would exist for co-examination of claims, the Examiner must show that examination of the

FISCHER et al. Application No.: 09/553,690 Page 2

claims would involve substantially different prior art searches, making the co-examination burdensome.

2. A Search of the Sequences Recited in Independent Claims 1, 21, 47 and 58 Will Identify Art Relevant to the Claims of Group II

Restriction Groups I, II and IV were apparently restricted by the Examiner because the groups encompass different sequences (encoding SEQ ID NOs:2, 20 and 22, respectively) exemplified in the specification. Applicants submit that the present application describes a non-Markush genus of polynucleotides (e.g., as recited in claims 1, 21, 47 and 58) that encompasses all polynucleotides encoding the particular sequences recited in the dependent claims (e.g., SEQ ID NOs:2, 20, and 22). Therefore, it is appropriate to include claims 1, 21, 47 and 58 in each of Groups I, II and IV.

The sequences exemplified in the specification are not sequences with different functions or structures that merely happen to be described in the same specification. Instead, the specification describes and claims 1, 21, 47 and 58 recite a common structural motif (e.g., the B domain). Furthermore, the genus of sequences have a common functional role in plants (e.g., the development of embryonic tissue). In light of these common functional and structural features, a search of the sequences recited in claim 1 will effectively search all of the exemplified sequences.

The common structure is reflected in the relation between the sequences recited in claim 1 and the sequences in Group II. In particular, some sequences at least 68% identical to the B domain of SEQ ID NO:2 are subsequences of polynucleotides encoding SEQ ID NO:20. Thus, sequences comprising at least 68% identity with the B domain of SEQ ID NO:2 include polynucleotides encoding SEQ ID NO:20. For example, the subject matter of claims 4-5 is completely encompassed by claim 1. Therefore, a search of claim 1 will identify all art relevant to claims 4-5. Similarly, claims 23-24 are encompassed by claim 21, claims 50-51 are encompassed by claim 47 and claims 59-60 are encompassed by claim 58. Searches of each independent claim will identify all relevant art for the respective dependent claims. Accordingly, Applicants request that the Examiner include claims 1, 21, 47 and 58 into Groups II and IV as well as Group I.

FISCHER et al.

Application No.: 09/553,690

Page 3

3. Group VI, directed to antisense constructs, can be searched with sense constructs and therefore should be recombined with the remaining restriction groups

Claims 14, 34 and 65 (i.e., Group VI) are directed to aspects of the invention where polynucleotides encoding an LEC1 polypeptide are linked to a promoter in the antisense orientation. However, independent claims 1, 21 and 58, which are included in Group I, encompass the subject matter of claims 14, 34 and 65. For example, claim 1 is generally directed to expression cassettes encoding LEC1 polypeptides. Claim 14 is directed to the same polynucleotides linked to a promoter in the antisense orientation. Thus, all art relevant to claim 14 would be identified in a search of claim 1. Similarly, since claims 21 and 58 are broader than claims 34 and 65, a search of claims 21 and 58 is sufficient to identify all art relevant to claims 34 and 65.

Accordingly, Applicants request that the Examiner examine claims 14, 34 and 65 with Group I, II or IV, any of which encompass antisense constructs.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,

Matthew E. Hinsch Reg. No. 47,651

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834 Tel: (415) 576-0200

Fax: (415) 576-0300 MEH

MEH SF 1268606 v1

PTO/SB/21 (08-00)

type a plus sign (+) inside this box

+ Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE er the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSM			Applic	ation Number	09/516,052	PEC
TRANSMITTAL FORM (to be used for all correspondence after initial filing) Total Number of Pages in This Submission			Filing Date		March 1, 2000	
			First Named Inventor		Harada, John SEP 2	
			Group	Art Unit	1638	
			Exami	ner Name	C. Collins	TECH CENT
			Attorn	ey Docket Number	02307O077630	
		ENCL	OSURES	(check all that apply)		
Fee Transmittal Form		Assignment P				e Communication to
Fee Attached		☐ Drawing(s)			Appeal Communication to Board of Appeals and Interferences	
Amendment / Response		Licensing-related Papers			Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)	
After Final		Petition Routing Slip (PTO/SB/69) and Accompanying Petition		Proprietary Information		
Affidavits/declaration(s)		Petition to Convert to a Provisional Application		Status Letter		
Extension of Time Request		Power of Attorney, Revocation Change of Correspondence Address		Other Enclosure(s) (please identify below):		
Express Abandonment Request		☐ Terminal Disclaimer ☐ Request for Refund		Return Postcard		
☐ Information Disclosure Statement		_	umber of			
Certified Copy of Priority Document(s)			Remarks The Commissioner is authorized to charge any additional fees Deposit Account 20-1430.			
Response to Missing Pa	arts/			}		
Response to Missin Parts under 37 CFR 1.52 or 1.53						
	SIGNA	TURE OF	APPLIC	ANT, ATTORNEY,	OR AGENT	
and	nsend and Tov		Crew LLF			
Individual name Matt	hew E. Hinsch		1	Reg N	No. 47,651	
Signature		1.				
Date Sept	ember 17, 200)1				
		CE	RTIFICA	TE OF MAILING		
I hereby certify that this corr class mail in an envelope ac	espondence is ddressed to: A	s being depo ssistant Con	osited with nmissione	the United States Poer for Patents, Washin	gton, D.C. 20231 on th	ient postage as first nis date: mber 17, 2001

Burden Hour Statement: This form is estimated to taMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. SF 1269909 v1